Biological Forum – An International Journal **15(3): 669-674(2023)**

ISSN No. (Print): 0975-1130
ISSN No. (Online): 2249-3239

Explore Role of Antihistamines for the Treatment of Allergic Disorders

Kiran Mahajan*, Wagh Bhakti, Shubhrajit Mantry, Shital Bidkar and Ganesh Dama
Department of Pharmaceutics SGMSPM's Sharadchandra Pawar College of Pharmacy, Dumbarwadi (Otur), Pune (Maharashtra), India.

(Corresponding author: Kiran Mahajan, kirancmahajan@gmail.com)*
(Received: 21 January 2023; Revised: 22 February 2023; Accepted: 24 February 2023; Published: 22 March 2023)
(Published by Research Trend)

ABSTRACT: In terms of prevalence, most of allergic diseases conditions that last the patient's entire lifetime. It's not just that patients' quality of life plummets, but that they miss a lot of work and are less productive as a result, driving up huge expenditures for society. Thus, finding reliable methods to treat allergic illnesses is a major concern for public health. In addition to allergists, otolaryngologists, and dermatologists, all family medicine specialists, internists, and paediatricians should do this. Antihistamines are most commonly used for allergy treatment. Asthma, eczema, and other allergic illnesses can be treated with any number of drugs already on the market, many of which have generic equivalents that receive extensive advertising. Just what is reality, anyway? What do clinical trials and large-scale observational studies tell us? Is there a standard for how well (and how safely) drugs work? Medical experts from a variety of fields came to the conclusion that mishandling patients' allergies might have devastating consequences, and that drugs with seemingly comparable effects don't always have the same. Hence, a team of experts has assembled the most recent. We scoured the most up-to-date recommendations and standards from professional scientific organisations, as well as the whole corpus of scientific literature. This essay reviews that study and stresses the relevance of the patient choosing the appropriate medication for his allergies.

Keywords: Histamine H1-receptor, Ist generation antihistamines, IInd generation antihistamines, Allergy, Urticaria.

INTRODUCTION

Histamine is ubiquitous in animal tissues and can even be found in some plants like stinging nettle. Around the turn of the 20th century, Dale began exploring its pharmacology after discovering a remarkable similarity between its effects and the symptoms of some allergic reactions. It has been found that histamine can lessen the severity of hypersensitivity and tissue damage reactions. It has recently been discovered that ten plays crucial physiological roles. Mast cells store histamine mostly in granules. Histamine is abundant in various organs and tissues, including the skin, lungs, liver, and placenta. Non-mast cell histamine is found in the brain, skin, gut mucosa, and developmental tissues. Mast cells have a slow rate of histamine turnover compared to other cell types, where histamine is rapidly recycled. Most body fluids, including blood, venoms, and pathological fluids, include histamine. Table 1 provides an overview of the many categories into which antihistamines fall.

Table 1: Classification of Antihistamines.

Chemical Class	First generation	Second generation
Alkylamines	Pheniramine, Chlorpheniramine, Clemastine, Cyproheptadine, Diphenhydramine, Promethazine	Acrivastine
Piperazines	Hydroxyzine	Certizine, Levocetrizine
Piperidines	Ketotifen, Cyproheptadine,	Astemizole, Desloratadine, Fexofenadine, Loratadine, Mizolastine, Olopatadine, Terfenadine, Bilastine
Ethanolamines	Doxylamine, Dimenhydrinate, Diphenhydramine,	-
Phenothiazines	Promethazine	-
Others	Doxepin	Azelastine

PHARMACOLOGY

Antihistamines work because they attach to histamine receptors, which are found on the cell surface. Four types of histamine receptors in the body (H1-H4), with H1 and H2 being the most common. Eosinophils, neutrophils, epithelial cells, vascular smooth muscle cells and smooth muscle cells of the airways and lungs are just few of the cell types that have been found to possess H1 histamine receptors (Del Cuvillo *et al.,* 2006). Many cell types, including eosinophils, neutrophils, vascular smooth muscle cells, endothelial cells, and airway and pulmonary smooth muscle cells, include H1 histamine receptors (Simons *et al.,* 2008).

Although the receptors attach histamine, they are also able to signal constitutively in the absence of histamine binding at the cell surface. The ratio of functional receptors to inactive receptors is stable. The receptor's active form is stabilised by histamine, while the inactive form is maintained by antihistamines. Consequently, H1 antihistamines play the role of antagonists. In contrast to cetirizine, desloratadine, and fexofenadine, loratadine is metabolised in the liver. Fexofenadine is eliminated in the faeces while cetirizine is eliminated in the pee. Those with severe hepatic or renal failure may benefit from a reduced dose.

THE H1-RECEPTOR FOR HISTAMINE

GPCR, which include the human histamine H1 receptor, are a distinct family of proteins. At least 500 distinct membrane proteins belong to this superfamily, and they share a general structural motif of seven transmembrane alpha-helical segments (Leurs *et al.,* 2001; Hill *et al.,* 2001). A protein of 487 amino acids and 55.8 kDa is encoded by the histamine H1-receptor gene (Fukui *et al.,* 1994; De Backer *et al.,* 1998). Since the H1-receptor gene is intron-free, only a single receptor protein is produced during transcription; alternative splicing is therefore impossible (McCudden *et al.,* 2005). Like other G-protein-coupled receptors, the histamine H1-receptor has a "on" and "off" state that coexist in an equilibrium. Histamine stabilises the active conformation of the H1 receptor for histamine by cross-linking sites on transmembrane domains III and V, thus moving the equilibrium to the on position (Wieland *et al.,* 1999).

Since they are structurally distinct from histamine, H1-antihistamines do not inhibit the attachment of histamine but, rather, have the opposite effect by attaching to specific receptor sites. Transmembrane domains IV and VI are connected by cetirizine, which acts as a stabiliser. As the receptor enters its dormant state, the balance shifts to the off position. H1-antihistamines, contrary to popular belief, are not antagonists but rather antagonist of the histamine H1 receptor (Leurs R *et al.,* 2022; Bousque *et al.,* 2001). This has led to "H1-antihistamines" replacing "histamine antagonists" as the preferred term for these drugs.

ROLE OF NEWEST ANTIHISTAMINES IN ALLERGIC RHINITIS AND ALLERGIC CONJUNCTIVITIS

It is recommended that while prescribing an anti-H1 medication, one should prioritise those with the least potential for sedative effect, the widest therapeutic index, the most favourable pharmacokinetics, and the fewest possible drug interactions (Bousque *et al.,* 2001). This is because inhalational exposure to the allergen causes or exacerbates the symptoms. The patient may occasionally report feeling tired, having trouble paying attention, or snoring.

They are detrimental to one's personal and professional development. Allergic rhinitis, if not treated adequately or undertreated, can lead to complications in the ears, paranasal sinuses, and lower respiratory system. Prevalence of allergic rhinitis was measured at 22.4% of the sample population through the ECAP trial (Samoliński *et al.,* 2009). To further complicate matters, allergic rhinitis frequently manifests with conjunctivitis. Eye symptoms, such as itchiness, redness, and watering, may emerge before nose symptoms. Allergy rhinitis and allergic conjunctivitis are often confused with one another because they occur so frequently together (such as allergic rhino conjunctivitis). Allergic rhinitis can have a serious negative effect on a person's standard of living.

Recent research has classified atopic rhinitis according to its trigger allergens and duration of openness time into infrequent, chronic, and word-related forms. They determined the difference between seasonal allergic rhinitis and chronic allergic rhinitis (wherein symptoms persist for more than four weeks and more than four days per week) (with symptoms lasting for less than four days in week) (Bousque *et al.,* 2001).

THE MOST RECENT ANTIHISTAMINIC FOR URTICARIA MANAGEMENT

Addition to receptor, an exceptionally wide board of different middle people is likewise engaged with urticaria clinical appearance, and both the combination and arrival of these go between are subject to various, sometimes complex etiologic and setting factors, which sadly often remain hazy (Ferrer *et al.,* 2015; Zuberbier *et al.,* 2003).

TREATMENT OF UPPER RESPIRATORY TRACT VIRAL INFECTIONS WITH ANTIHISTAMINES

Taking into mind the pathophysiology of the ailment, the second generation of non-sedative antihistamines may improve the quality of life of patients with upper respiratory tract infections by lowering symptoms (De Sutter *et al.,* 2015).

It appears that the anti-inflammatory activity independent of the H1 receptor may be significantly more important than the modest effect of inhibiting the receptor itself. Perhaps a drug like bilastine, which inhibits the formation of inflammatory cytokines like interleukin-6 and IL-8, would be helpful (Krause *et al.,* 2013).

ANTIHISTAMINES: THEIR PAST, PRESENT, AND FUTURE. WHAT SHOULD BE TAKEN INTO ACCOUNT FROM THE PHARMACOLOGIST'S VIEWPOINT?

Among therapeutic drugs, the IInd -generation antihistamines are the first choice because of the improvements made to their mechanism of action. Most, if not all, of the original drugs are completely useless now. For the short-term relief of cold and flu symptoms, they are used as anticholinergic components of more complex medicines. Congestion and rhinitis are symptoms of a more serious condition, and A1 adrenolytic action may be harmful for patients who also suffer from these conditions. The second generation of medicines is, without a question, a diverse collection. Their pharmacokinetic and pharmacodynamic aspects are often used as selection criteria because of this.

Clinically, the adverse event profile and interactions of antihistamines are major factors in making a selection. Possible complications with allergy disease management could arise if this is ignored during combination therapy. In terms of pharmacokinetics and pharmacodynamics, Bilastine is the antihistamine with the fewest potential for drug interactions (Helwig *et al.* 2011; Babu *et al.,* 2013).

H1-ANTIHISTAMINES' EFFECTIVENESS IN TREATING ALLERGIC DISORDERS

H1 antihistamines should be taken regularly. In the past 60 years, few Ist -generation H1 antihistamine randomised, placebo-controlled clinical trials have fulfilled current standards. Hundreds of properly conducted randomised, placebo-controlled clinical trials lasting weeks or months that clearly state inclusion and exclusion criteria and document attrition and adherence support the use of II nd -generation H1 antihistamines to treat allergic rhinoconjunctivitis and chronic urticaria. Hence, second-generation H1 antihistamines treat allergic rhinitis, allergic conjunctivitis, and chronic urticaria better (Simons *et al.,* 2002; Anonymous*.,* 2007; Plaut *et al.,* 2005; Juniper *et al.,* 2005; Bousquet *et al.,* 2001).

HAY FEVER AND ALLERGIC CONJUNCTIVITIS

ARIA 2008 and 2010 reviews recommend oral or intranasal second-generation antihistamines for mild, moderate, or severe chronic and periodic allergic rhinitis (Bousquet *et al.,* 2008; Brozek *et al.,* 2010). Antihistamines and nasal glucocorticoids cure moderate-to-severe chronic allergic rhinitis (Brozek *et al.,* 2010). Second-generation antihistamines and nasal glucocorticosteroids are available for children over 12 (Carr *et al.,* 2012). Antihistamines for allergic conjunctivitis in children are justified. (Silny *et al.,* 2012) This indication lacks substantial efficacy evidence. Pediatricians still augment this sickness with the first and second generations of antihistamines (Van Zuuren *et al.,* 2014; Darsow *et al.,* 2010). Pediatrics with sleep problems due to pruritus and acute allergic conjunctivitis may benefit from the Ist generation of antihistamines, which are sedative and anti-itching (Akdis *et al.,* 2006). Figure 1 shows Allergic rhinitis symptoms.



Fig. 1. Allergic Rhinitis.

MARKET ANALYSIS AND SIZE OF ANTIHISTAMINIC DRUGS

Antihistamines relieve histamine-induced itching. They cure urticaria, allergic conjunctivitis, and rhinitis. Newer antihistamines don't sedate. Second-generation H1-antihistamines treat allergies safely and effectively. Levocetirizine and fexofenadine have the highest in vivo potency in humans. Fexofenadine's acute action may require twice-daily dosing for all-day protection. Nevertheless, levocetirizine may cause drowsiness. Table 2 lists commercial antihistaminic formulations.

Table 2: Marketed formulations of Antihistaminic drug.

Brand Name	Generic Name	Formulation
Allegra ™	Fexofenadine Hydrochloride Tablets I.P.	Tablet
Claritin	Loratidine tablets	Tablets
Drozix – 10	Hydroxine Hydrochloride Tablets I.P.	Tablet
Benadryl	Diphenhydramine HCL oral solution	Oral Solution
Aerius	Desloratidine tablets	Tablet
Alerid	Cetrizine syrup I.P.	Syrup
Zyrtec	Cetrizine dihydrochloride oral solution	Oral solution
Lanzin	Levocetrizine tablets	Tablet
Triaminic thin strips	Diphenhydramine Hydrochloride	Thin strips

H1 ANTIHISTAMINE SIDE EFFECTS

ANTIHISTAMINES OF THE H1 FIRST GENERATION

Antihistamines may harm various body systems (Simons *et al.,* 2004; Simons *et al.,* 2008; Holgate *et al.,* 2003; Hansen *et al.,* 2005; Wyngaarden *et al.,* 1951). All first-generation H1 antihistamines affect histamine-mediated neurotransmission at CNS H1 receptors, over 70% of Brain H1 receptors (Tashiro *et al.,* 2004). Its lipophilicity, low molecular weight, and lack of substrate recognition by the P glycoprotein efflux pump on non-fenestrated endothelial cells in the CNS vasculature let them traverse the blood-brain barrier. Randomized controlled investigations with electroencephalographic monitoring, sleep latency evaluations, and common performance tests from simple response time tests to hard sensorimotor activities like computer-monitored driving have shown central nervous system penetration (Simons *et al.,* 2004; Simons *et al.,* 2008; Holgate *et al.,* 2003; Hansen *et al.,* 2005; Wyngaarden *et al.,* 1951; Tashiro *et al.,* 2004; Hindmarch *et al.,* 2001; Shamsi *et al.,* 2000; Casale *et al.,* 2003). Even at low doses, first-generation H1 antihistamines impair Brain function. First-generation H1 antihistamines have CNS effects comparable to or worse than ethanol or other CNS-active drugs (Simons *et al.,* 2004; Simons *et al.,* 2008).

H1 ANTIHISTAMINES OF THE SECOND GENERATION

Recent H1 allergy medicines enter the CNS poorly and have between 0% (fexofenadine, up to 360 mg) and 30% (cetirizine, above 20 mg) H1 receptors in the CNS. Second-generation H1 antihistamines are unlikely to affect the CNS (CNS). Loratadine and cetirizine can cause drowsiness if doses are exceeded. Fexofenadine, an H1 antihistamine, is the least sedative of these medications (Simons *et al.,* 2004; Simons *et al.,* 2008; Holgate *et al.,* 2003; Hansen *et al.,* 2005; Wyngaarden *et al.,* 1951; Tashiro *et al.,* 2004; Hindmarch *et al.,* 2001; Shamsi *et al.,* 2000; Casale *et al.,* 2003). Alcohol and other CNS-active substances do not worsen second-generation H1 antihistamines. In real-world prescription-event monitoring studies on thousands of allergic rhinitis patients in the UK within the first 30 days after the launch of a new H1 antihistamine, cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine had a low risk of sedation (Mann *et al.,* 2000; Layton *et al.,* 2006). As astemizole and terfenadine lost regulatory approval two decades ago, the remaining second-generation H1 antihistamines have no cardiac adverse effects. These medicines are safe long-term, according to randomised, controlled trials (Simons *et al.,* 2004; Simons *et al.,* 2008; Holgate *et al.,* 2003; Hansen *et al.,* 2005). Randomized, controlled, and masked desloratadine, fexofenadine, and levocetirizine investigations lasted six to twelve months for adults and twelve to eighteen months for very young children (Hansen *et al.,* 2005; Bachert *et al.,* 2004; Simons *et al.,* 1999; Simons *et al.,* 2007; Grimfeld *et al.,* 2004).

CONCLUSION

Antihistamines relieve histamine-induced itching. They cure urticaria, hypersensitive conjunctivitis, and rhinitis. Newer antihistamines are less sedative. Several safe and effective second-generation H1-antihistamines address allergies. Levocetirizine and fexofenadine are the strongest in vivo of the three drugs in this assessment. Nevertheless, fexofenadine's limited duration of action may require twice-day administration for daily protection. Levocetirizine may produce somnolence in vulnerable people. Desloratadine is weaker but has a lengthy half-life and rarely causes tiredness.

Acknowledgement. We acknowledge the generous research infrastructure and supports from SPCOP College of Pharmacy, Otur, Pune, Maharashtra, India.

Conflict of Interest. None.

REFERENCES

Akdis, C. A., Akdis, M., Bieber, T., Bindslev-Jensen, C., Boguniewicz, M., Eigenmann, P., Hamid, Q., Kapp, A., Leung, D. Y. M., Lipozencic, J., Luger, T. A., Muraro, A., Novak, N., Platts-Mills, T. A. E., Rosenwasser, L., Scheynius, A., Simons, F. E. R., Spergel, J., Turjanmaa, K., Wahn, U., Weidinger, S., Werfel, T., Zuberbier, T. (2006). Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. *Allergy, 61*(8), 969–987.

Anonymous (2007) Drugs for allergic Disorders. *Treatment Guidelines from The Medical Letter*, (60), 71Y80.

Babu, K. S., Polosa, R. and Morjaria, J. B. (2013). Anti-IgE – emerging opportunities for Omalizumab. *Expert Opinion on Biological Therapy, 13*(5), 765–777.

Bachert, C., Bousquet, J., Canonica, G. W., Durham, S. R., Klimek, L., Mullol, J., Van Cauwenberge, P. and Van Hammée, G. (2004). Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. *The Journal of Allergy and Clinical Immunology*, *114*(4), 838–844.

Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A., Zuberbier, T., Baena-Cagnani, C.E., Canonica, G.W., Van Weel, C., Agache, I., Aït-Khaled, N., Bachert, C., Blaiss, M.S., Bonini, S., Boulet, L. P., Bousquet, P. J., Camargos, P., Carlsen, K. H., Chen, Y., Custovic, A., Dahl, R., Demoly, P., Douagui, H., Durham, S.R., Van Wijk, R.G., Kalayci, O., Kaliner, M.A., Kim, Y. Y., Kowalski, M.L., Kuna, P., Le, L.T.T., Lemiere, C., Li, J., Lockey, R.F., Mavale-Manuel, S., Meltzer, E.O., Mohammad, Y., Mullol, J., Naclerio, R., O'Hehir, R.E., Ohta, K., Ouedraogo, S., Palkonen, S., Papadopoulos, N., Passalacqua, G., Pawankar, R., Popov, T.A., Rabe, K.F., Rosado-Pinto, J., Scadding, G.K., Simons, F.E.R., Toskala, E., Valovirta, E., Van Cauwenberge, P., Wang, D. Y., Wickman, M., Yawn, B.P., Yorgancioglu, A., Yusuf, O.M., Zar, H., Annesi-Maesano, I., Bateman, E.D., Kheder, A.B., Boakye, D.A., Bouchard, J., Burney, P., Busse, W.W., Chan-Yeung, M., Chavannes, N.H., Chuchalin, A., Dolen, W.K., Emuzyte, R., Grouse, L., Humbert, M., Jackson, C., Johnston, S.L., Keith, P.K., Kemp, J.P., Klossek, J. M., Larenas-Linnemann, D., Lipworth, B., Malo, J. L., Marshall, G.D., Naspitz, C., Nekam, K., Niggemann, B., Nizankowska-Mogilnicka, E., Okamoto, Y., Orru, M.P., Potter, P., Price, D., Stoloff, S.W., Vandenplas, O., Viegi, G. and Williams, D. (2008), Allergic Rhinitis and its Impact on Asthma (ARIA). *Allergy, 63*: 8-160.

Bousquet, J., Van Cauwenberge, P. and Khaltaev, N. (2001). Allergic Rhinitis and Its Impact on Asthma. *The Journal of Allergy and Clinical Immunology, 108*(5), 147–334.

Brozek, J. L., Bousquet, J., Baena-Cagnani, C. E., Bonini, S., Canonica, G. W., Casale, T. B., Van Wijk, R. G., Ohta, K., Zuberbier, T., Schünemann, H. J., Global Allergy and Asthma European Network and Grading of Recommendations Assessment, Development and Evaluation Working Group (2010). Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. *The Journal of allergy and clinical immunology*, *126*(3), 466–476.

Carr, W., Bernstein, J. A., Lieberman, P., Meltzer, E. O., Bachert, C., Price, D., Munzel, U. and Bousquet, J. (2012). A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. *The Journal of Allergy and Clinical Immunology*, *129*(5), 1282-1289.

Casale, T. B., Blaiss, M. S., Gelfand, E. W., Gilmore, T., Harvey, P. D., Hindmarch, I., Simons, F. E. R., Dl, S., Szefler, S. J., Terndrup, T. E., Waldman, S. A., Weiler, J. M. and Wong, D. F. (2003). First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. *The Journal of Allergy and Clinical Immunology*, *111*(5), 835–842.

Darsow, U., Wollenberg, A., Simon, D., Taïeb, A., Werfel, T., Oranje, A. P., Gelmetti, C., Svensson, A., Deleuran, M., Calza, A., Giusti, F., Lübbe, J., Seidenari, S. and Ring, J. (2010). ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. *Journal of the European Academy of Dermatology and Venereology*, *24*(3), 317–328.

De Backer, M. D., Loonen, I. C., Verhasselt, P., Neefs, J. and Luyten, W. (1998). Structure of the human histamine H1 receptor gene. *Biochemical Journal*, *335*(3), 663–670.

De Sutter, A., Saraswat, A. and Van Driel, M. L. (2015). Antihistamines for the common cold. *The Cochrane Library*, *2015*(11).

Del Cuvillo, A., Mullol, J., Bartra, J., Dávila, I., Jáuregui, I., Montoro, J., Sastre, J. and Valero, A. L. (2006). Comparative pharmacology of the H1 antihistamines. *Journal of investigational allergology & clinical immunology*, *16 Suppl 1*, 3–12.

Ferrer, M. (2015). Immunological events in chronic spontaneous urticaria. *Clinical and Translational Allergy*, *5*(1), 30.

Fukui, H., Fujimoto, K., Mizuguchi, H., Sakamoto, K., Horio, Y., Takai, S., Yamada, K., & Ito, S. (1994). Molecular Cloning of the Human Histamine H1 Receptor Gene. *Biochemical and Biophysical Research Communications*, *201*(2), 894–901.

Grimfeld, A., Holgate, S. T., Canonica, G. W., Bonini, S., Borres, M. P., Adam, D., Canseco Gonzalez, C., Lobaton, P., Patel, P., Szczeklik, A., Danzig, M. R., Roman, I., Bismut, H. and Czarlewski, W. (2004). Prophylactic management of children at risk for recurrent upper respiratory infections: the Preventia I Study. *Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology*, *34*(11), 1665–1672.

Hansen, J., Klimek, L. and Hörmann, K. (2005). Pharmacological management of allergic rhinitis in the elderly: safety issues with oral antihistamines. *Drugs & aging*, *22*(4), 289–296.

Helwig and Otto Arzneimittel (2011). A Handbook for Doctors and Pharmacists, Stuttgart, Germany. *Der Deutsche Apotheker Verlag, 15*(4), 221-222.

Hill S. J. (2006). G-protein-coupled receptors: past, present and future. *British journal of pharmacology*, *147 Suppl 1*(Suppl 1), 27–37.

Hindmarch, I., Johnson, S., Meadows, R., Kirkpatrick, T. and Shamsi, Z. (2001). The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. *Current medical research and opinion*, *17*(4), 241–255.

Holgate, S. T., Canonica, G. W., Simons, F. E., Taglialatela, M., Tharp, M., Timmerman, H., Yanai, K. and Consensus Group on New-Generation Antihistamines (2003). Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. *Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology*, *33*(9), 1305–1324.

Juniper, E. F., Ståhl, E., Doty, R. L., Simons, F. E., Allen, D. B. and Howarth, P. H. (2005). Clinical outcomes and adverse effect monitoring in allergic rhinitis. *The Journal of allergy and clinical immunology*, *115*(3 Suppl 1), 390–413.

Krause, K., Spohr, A., Zuberbier, T., Church, M. J. and Maurer, M. (2013). Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. *Allergy*, *68*(7), 921–928.

Layton, D., Wilton, L., Boshier, A., Cornelius, V., Harris, S. and Shakir, S. A. (2006). Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. *Drug safety*, *29*(10), 897–909.

Leurs, R., Church, M. J., & Taglialatela, M. (2002). H_1 -antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. *Clinical & Experimental Allergy*, *32*(4), 489–498.

Leurs, R., Watanabe, T., & Timmerman, H. (2001). Histamine receptors are finally 'coming out.' *Trends in Pharmacological Sciences*, *22*(7), 337–339.

Mann, R. J., Pearce, G. L., Dunn, N. and Shakir, S. W. (2000). Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice Commentary: Reporting of adverse events is worth the effort. *BMJ*, *320*(7243), 1184–1187.

McCudden, C. R., Hains, M. D., Kimple, R. J., Siderovski, D. P. and Willard, F. (2005). G-protein signaling: back to the future. *Cellular and Molecular Life Sciences*, *62*(5), 551–577.

Plaut, M. and Valentine. (2005). Allergic Rhinitis. *The New England Journal of Medicine*, *353*(18), 1934–1944.

Samoliński, B., Sybilski, A. J., Raciborski, F., Tomaszewska, A., Samel-Kowalik, P., Walkiewicz, A., Lusawa, A., Borowicz, J., Gutowska-Slesik, J., Trzpil, L., Marszałkowska, J., Jakubik, N., Krzych, E., Komorowski, J., Lipiec, A., Gotlib, T., Samolińska-Zawisza, U. and Hałat, Z. (2009). Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. *Otolaryngologia polska. The Polish otolaryngology*, *63*(4), 324–330.

Shamsi, Z., & Hindmarch, I. (2000). Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. *Human Psychopharmacology*, *15*(S1), 3–30.

Silny, W., Gliński, W. and Czarnecka-Operacz, M. (2005). Leki przeciwhistaminowe w terapii dermatologicznej. *Leki przeciwhistaminowe. Zastosowanie w praktyce medycznej. Wydanie II, Bruksela, Belgia: The UCB Institute of Allergy,* P(3), 101–121.

Simons, F. E. and Simons, K. J. (2011). Histamine and H1-antihistamines: celebrating a century of progress. *The Journal of allergy and clinical immunology*, *128*(6), 1139–1150.e4.

Simons, F. E. and Simons, K. J. (2008). H1 antihistamines: current status and future directions. *The World Allergy Organization journal*, *1*(9), 145–155.

Simons, F. E. R. and Akdis, C. A. (2008). Histamine and antihistamines. *Middleton's allergy principles and practice. 7th ed. St Louis, MO: Mosby, Inc, [an affiliate of Elsevier Science],* (2), 1517-1547.

Simons, F. E. and Early Prevention of Asthma in Atopic Children (EPAAC) Study Group (2007). Safety of levocetirizine treatment in young atopic children: An 18-month study. *Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology*, *18*(6), 535–542.

Simons, F. E. (1999). Prospective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic Child. *The Journal of allergy and clinical immunology*, *104*(2 Pt 1), 433–440.

Simons F. E. R. (2002). H1-antihistamines in children. *Clinical allergy and immunology, 17,* 437–464.

Simons F. E. (2004). Advances in H1-antihistamines. *The New England journal of medicine*, *351*(21), 2203–2217.

Tashiro, M., Sakurada, Y., Iwabuchi, K., Mochizuki, H., Kato, M., Aoki, M., Funaki, Y., Itoh, M., Iwata, R., Wong, D. F. and Yanai, K. (2004). Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. *Journal of clinical pharmacology*, *44*(8), 890–900.

Van Zuuren, E. J., Apfelbacher, C. J., Fedorowicz, Z., Jupiter, A., Matterne, U. and Weisshaar, E. (2014). No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review. *Systematic reviews*, *3*, 25.

Wieland, K., Laak, A. M., Smit, M. J., Kühne, R., Timmerman, H. and Leurs, R. (1999). Mutational analysis of the antagonist-binding site of the histamine H(1) receptor. *The Journal of biological chemistry*, *274*(42), 29994–30000.

Wyngaarden, J. B., & Seevers, M. H. (1951). The Toxic effects of Anti-Histaminic Drugs. *Journal of the American Medical Association*, *145*(5), 277.

Zuberbier T. (2003). Urticaria. *Allergy*, *58*(12), 1224–1234.

How to cite this article: Kiran Mahajan, Wagh Bhakti, Shubhrajit Mantry, Shital Bidkar and Ganesh Dama (2023). Explore Role of Antihistamines for the Treatment of Allergic Disorders. *Biological Forum – An International Journal, 15*(3): 669-674.